Neusilin US2 based Liquisolid Compact technique for the enhancement of solubility and dissolution rate of Olmesartan: Box-Behnken design approach

Year 2023, Volume: 27 Issue: 1, 52 - 66, 28.06.2025

Dr. Abhishek Kanugo , Anushka Thanvi

Abstract

The therapeutic efficacy of an active ingredients are imperfect owing to the poor solubility and dissolution rate. Moreover, dissolution is the rate-limiting period towards the absorption and bioavailability of the active ingredients. Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) recommended for the therapy of high blood pressure as well as minimizes the chances of stroke, heart attack and kidney problems. Olmesartan medoxomil is a BCS class II molecule with only 26 % bioavailability. Hence, the current research work was focused on cost-effective Liquisolid technology for the improvement of solubility, dissolution rate and thereby achieving higher therapeutic efficacy. Liquisolid Compact is one of the best technique for improvement of solubility of potent hydrophobic molecules by utilizing non-volatile solvent. The solubility of olmesartan was estimated in several non-volatile solvents and tween 80 (95 mg/ml) was found to be best. The formed liquid medicaments were converted into the free-flowing powder blends for direct compression by the addition of carrier (Dibasic anhydrous calcium phosphate) and coating agent (Neusilin US2). The drug-excipients compatibilities were confirmed with FTIR. QbD design (Box-Behnken) was applied which comprised of independent factors (X1: DCP, X2: Neusilin US2, X3: CCS) and dependable factors were (Y1: Disintegration time, Y2: Dissolution release). The Design of expert software (DOE, Statease, Version 11) showed 12 batches which were evaluated for their flowing characteristics. The optimized batch F12 showed excellent flowing characteristics (Carr’s index: 14, Angle of repose: 24.42), rapid disintegration time (2.07 min), in-vitro drug release (99.45%) and qualify under accelerated stability testing with minimal drug loss.

Keywords

Olmesartan , solubility enhancemen , Liquisolid , Box-Behnken design , neusilin US2

References

• [1] Rojekar S V., Trimukhe AM, Deshmukh RR, Vavia PR. Novel pulsed oxygen plasma mediated surface hydrophılizatıon of ritonavır for the enhancement of wettability and solubility. J Drug Deliv Sci Technol. 2021 Jun 1;63:102497. [CrossRef]
• [2] Khan KU, Minhas MU, Badshah SF, Suhail M, Ahmad A, Ijaz S. Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs. Life Sci. 2022 Feb 15;291:120301. [CrossRef]
• [3] Khan KU, Minhas MU, Badshah SF, Sohail M, Sarfraz RM. β-cyclodextrin modification by cross-linking polymerization as highly porous nanomatrices for olanzapine solubility improvement; synthesis, characterization and bio-compatibility evaluation. J Drug Deliv Sci Technol. 2022 Jan 1;67:102952. [CrossRef]
• [4] Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res [Internet]. 1995 [cited 2022 Feb 19];12(3):413–20. Available from: https://pubmed.ncbi.nlm.nih.gov/7617530/. [CrossRef]
• [5] Huang Z, Staufenbiel S, Bodmeier R. Kinetic solubility improvement and influence of polymers on controlled supersaturation of itraconazole-succinic acid nano-co-crystals. Int J Pharm. 2022 Mar 25;616:121536. [CrossRef]
• [6] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997 Jan 15;23(1–3):3–25. [CrossRef]
• [7] Bazzo GC, Pezzini BR, Stulzer HK. Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs. Int J Pharm. 2020 Oct 15;588:119741. [CrossRef]
• [8] Papich MG, Martinez MN. Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls. AAPS J [Internet]. 2015 Jul 24 [cited 2022 Feb 19];17(4):948. Available from: /pmc/articles/PMC4476996/. [CrossRef]
• [9] Raza A, Hayat U, Bilal M, Iqbal HMN, Wang JY. Zein-based micro- and nano-constructs and biologically therapeutic cues with multi-functionalities for oral drug delivery systems. J Drug Deliv Sci Technol. 2020 Aug 1;58:101818. [CrossRef]
• [10] Tran P, Park JS. Application of supercritical fluid technology for solid dispersion to enhance solubility and bioavailability of poorly water-soluble drugs. Int J Pharm. 2021 Dec 15;610:121247. [CrossRef]
• [11] Kanugo A. Liquisolid-pellets technique: A recent technique for enhancing solubility and bioavailability of drugs. Int J Appl Pharm. 2020;12(6):34–40. [CrossRef]
• [12] US5800834A - Liquisolid systems and methods of preparing same - Google Patents [Internet]. [cited 2021 Sep 19]. Available from: https://patents.google.com/patent/US5800834A/en. [CrossRef]
• [13] Ghadi R, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. J Control Release. 2017 Feb 28;248:71–95. [CrossRef]
• [14] Shaikh F, Patel M, Patel V, Patel A, Shinde G, Shelke S, et al. Formulation and optimization of cilnidipine loaded nanosuspension for the enhancement of solubility, dissolution and bioavailability. J Drug Deliv Sci Technol [Internet]. 2022;69(November 2021):103066. [CrossRef]
• [15] Pathan LS, Modi CD, Gohel MC, Udhwani NH, Thakkar VT, Rana HB. Introducing novel hybridization technique for solubility enhancement of Bosentan formulation. Food Hydrocolloids for Health. 2022;2:100055. [CrossRef]
• [16] Kanugo AY, Kochar NI, Chandewar AV. Development of pulsatile drug delivery for chronotherapeutics of hypertension. Int J Drug Deliv Technol. 2017;7(3). [CrossRef]
• [17] Olmesartan: Uses, Interactions, Mechanism of Action | DrugBank Online [Internet]. [cited 2022 May 16]. Available from: https://go.drugbank.com/drugs/DB00275. [CrossRef]
• [18] Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J [Internet]. 2014;16(4):771–83. [CrossRef]
• [19] Kanugo AY, Kochar NI, Chandewar A. Pulsatile drug delivery of candesartan cilexetil for cardiovascular complications. Int J Pharm Sci Res 2017;8(9):3928–35.. [CrossRef]
• [20] Dholakiya A, Dudhat K, Patel J, Mori D. An integrated QbD based approach of SMEDDS and liquisolid compacts to simultaneously improve the solubility and processability of hydrochlorthiazide. J Drug Deliv Sci Technol. 2021;61:102162. [CrossRef]
• [21] Wang D, Xing H, Jiang J, Chen X, Yang T, Wang D, et al. Liquisolid technique and its applications in pharmaceutics. Asian J Pharm Sci. 2017 Mar 1;12(2):115–23. [CrossRef]
• [22] Bonthagarala B, Dasari V, Kotra V, Swain S, Beg S. Quality-by-Design based development and characterization of pioglitazone loaded liquisolid compact tablets with improved biopharmaceutical attributes. J Drug Deliv Sci Technol. 2019;51(March):345–55. [CrossRef]
• [23] Kanugo AY, Kochar NI, Chandewar A . Predictable Pulsatile Release of Candesartan Cilexetil for Chronotherapeutics of Hypertension. Int J Drug Dev Res. 2017;9(2):42–7. [CrossRef]
• [24] Kanugo AY, Kochar NI, Chandewar AV, Dhabarde DM, Dhawral VG. Design and evaluation of enteric compression-coated tablet for chronotherapeutic drug delivery. Asian J Pharm. 2017;11(3). [CrossRef]
• [25] Sharma S, Kanugo A, Gaikwad J. Design and development of solid lipid nanoparticles of tazarotene for the treatment of psoriasis and acne: a quality by design approach. Mater Technol. 2021;37(8): 735-743. [CrossRef]
• [26] Kanugo AY, Mathur VB. Evaluation and Comparison of Highly Soluble Sodium Stearyl Fumarate with Other Lubricants In Vitro. Indo Am J Pharm Res 2013;3:4042-4049.
• [27] Kanugo AY, Kochar NI, Chandewar AV. pH dependent pulsatile drug delivery for chronotherapeutics of cardiovascular diseases. Der Pharma Lettre 2017; 260–9.
• [28] Prajapat MD, Butani SB, Gohel MC. Liquisolid: A promising technique to improve dissolution efficiency and bioavailability of poorly water soluble nimodipine. J Drug Deliv Sci Technol. 2019;53(November 2018):101135. [CrossRef]
• [29] Jaipakdee N, Tabboon P, Limpongsa E. Application of a liquisolid technique to cannabis sativa extract compacts: Effect of liquid vehicles on the dissolution enhancement and stability of cannabinoids. Int J Pharm. 2022 Jan 25;612:121277. [CrossRef]
• [30] Kazaz Ç, Mesut B, Özsoy Y, Ocak M. Formulation development and evaluation of taste-masked atomoxetine hydrochloride orally disintegrating tablets (Odts). J Res Pharm. 2021;25(5):715–27. [CrossRef]
• [31] Kokott M, Lura A, Breitkreutz J, Wiedey R. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets. Eur J Pharm Biopharm [Internet]. 2021;168:122–30. [CrossRef]
• [32] Jaydip B, Dhaval M, Soniwala MM, Chavda J. Formulation and optimization of liquisolid compact for enhancing dissolution properties of efavirenz by using DoE approach. Saudi Pharm J [Internet]. 2020;28(6):737–45. Available from: https://doi.org/10.1016/j.jsps.2020.04.016. [CrossRef]
• [33] Han X, Shan X, Du Y, Pang S, Hu L. Development and evaluation of novel innovative multi-channel aripiprazole orally disintegrating tablets. J Drug Deliv Sci Technol. 2020 Feb 1;55:101446. [CrossRef]
• [34] Jaipakdee N, Limpongsa E, Sripanidkulchai B orn, Piyachaturawat P. Preparation of Curcuma comosa tablets using liquisolid techniques: In vitro and in vivo evaluation. Int J Pharm [Internet]. 2018;553(1–2):157–68. [CrossRef]
• [35] Huanbutta K, Yunsir A, Sriamornsak P, Sangnim T. Development and in vitro/in vivo evaluation of tamarind seed gum-based oral disintegrating tablets after fabrication by freeze drying. J Drug Deliv Sci Technol. 2019 Dec 1;54:101298. [CrossRef]